METACLIPSE THERAPEUTICS CORP — Department of Health and Human Services SBIR Phase I: NIAID

METACLIPSE THERAPEUTICS CORP — SBIR Phase I award from Department of Health and Human Services.

Amount
$230,270
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Topic
NIAID
NAICS
Place of performance
GA
Period

Description

The contractor will use engineered versions of IL and GM CSF as adjuvants The engineered version of IL and GM CSF include a glycosyl phosphatidylinositol GPI anchor at the carboxyl terminal which permits their incorporation into lipid bilayers such as influenza viral like particles VLP The development of the adjuvant will be in the context of influenza in elderly populations The specific tasks include the in vitro and in vivo establishment of an immunological profile of activity to evaluate the capability of the adjuvant